### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

### VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Common

Stock

Stock

Stock

11/18/2015

11/18/2015

11/18/2015

November 20, 2015

November 2	<i>'</i>							OMD AT			
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB APPROVAL			
								OMB Number:	3235-0287		
Check th	aer							Expires:	January 31,		
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Estimated average burden hours per response 0.5			
(Print or Type	Responses)										
1. Name and A	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]				5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)						
(Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 11/18/2015				Director 10% Owner Selection				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BOSTON, I	MA 02210						Form filed by M Person	Iore than One Re	porting		
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative S	ecurities Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transaction Code (Instr. 8)		es Acquired posed of (D) and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

(A)

or

(D)

Price

72.14

\$ 63.14

Amount

7,500

7,500

15,000 D

Transaction(s)

(Instr. 3 and 4)

82,500

90,000

\$ 130 75,000

D

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Code V

M

M

 $S^{(1)}$ 

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 8. I De Sec (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)			6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 72.14	11/18/2015		M		7,500	(2)	05/31/2024	Common Stock	7,500	
Stock Option (right to buy)	\$ 63.14	11/18/2015		M		7,500	<u>(3)</u>	05/23/2022	Common Stock	7,500	

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer

ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

EVP, Global Research and CSO

Other

## **Signatures**

Omar White, Attorney-In-Fact

\*\*Signature of Reporting Person Date

Reporting Owners 2

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- (2) Fully vested.
- (3) The option vests in 16 quarterly installments from 05/24/2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.